Nyvatex Oil (CE) (USOTC:NYVA)
Historical Stock Chart
From Oct 2019 to Oct 2024
Nyvatex Health-Mat(TM) Shown to Stimulate T-Cell Proliferation
BILLINGS, Mont., Sept. 21 /PRNewswire-FirstCall/ -- Nyvatex (OTC:NYVA)
announced today that an in vitro test of its patented Nyvalon(TM)
Health-Mat(TM) at a prominent Midwestern university showed a statistically
significant 55% improvement in T-cell proliferation in blood samples placed
with Nyvalon(TM) versus the control. Blood from 12 volunteers over 65 years of
age was tested by incubation in cultured media with and without PHA (which
activates T-cells).
Nyvalon(TM)'s effect on T-cells treated with PHA was not statistically
significant, but T-cells in culture media alone without PHA treatment
proliferated to a statistically significant value of 0.547 when exposed to
Nyvalon(TM), compared to 0.353 when not exposed to Nyvalon(TM). Nyvatex CEO
John C. Ledbetter stated that the improvement in non-PHA-treated T-cells
suggests that Nyvalon(TM) is encouraging proliferation of naive T-cells.
Describing the potential significance of the test results, Ledbetter stated:
"These results may offer an explanation for the substantial immune system
benefits reported over many years by users of the Nyvatex Health-Mat(TM). We
have seen that people who sleep on the Health-Mat(TM) do not suffer the annual
cough-cold-flu syndrome experienced by most of the U.S. population."
About Nyvalon(TM)
Nyvalon(TM) is the non-magnetic material inside the Nyvatex Health-Mat and
other Nyvatex health products that have been available for purchase from
Nyvatex since 1975 and have been used by thousands of individuals. The
material was developed at Nyvatex to assist in countering the negative effects
of living, working and traveling in Faraday cages, which insulate people from
the beneficial effects of exposure to the earth's natural fields.
About Nyvatex
Nyvatex Health Products is a wholly-owned subsidiary of Nyvatex Oil Corp., an
oil exploration company dedicated to the development of technologies premised
on naturally occurring geophysical phenomena. Nyvatex was founded in 1968.
Forward-Looking Statements
This press release contains forward-looking statements relating to
expectations, plans or prospects for Nyvatex, including its ability to expand
market awareness of Nyvalon(TM)-based products, its ability to further the
scientific rationale for the benefits of such products and its ability to
distribute these products to a broad segment of the population. These
possibilities are subject to numerous risks and uncertainties that could cause
actual results to differ materially from those described in the forward-looking
statements.
For further information: Tel (406) 252-3429 Fax (406) 252-6440
http://www.nyvatex.com/ e-mail:
John C. Ledbetter, CEO
Nyvatex, 3021 6th Avenue North, P.O. Box 1835, Billings, Montana 59103
DATASOURCE: Nyvatex
CONTACT: John C. Ledbetter, CEO of Nyvatex, +1-406-252-3429, or Fax,
+1-406-252-6440,
Web site: http://www.nyvatex.com/